期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
卷 5, 期 4, 页码 889-898出版社
ELSEVIER
DOI: 10.1016/j.jaip.2017.04.031
关键词
Childhood severe asthma; Difficult to treat asthma; Severe asthma phenotypes; Severe asthma treatment; Review
资金
- National Institutes of Health
- Aerocrine
- GlaxoSmithKline
- Genentech/Novartis
- Teva
- Boehringer Ingelheim
- scientific advisory board for Merck
- Cephalon
- DBV Technologies data safety monitoring board
- AstraZeneca
- American Board of Pediatrics/Pediatric Pulmonary Subboard
- Budesonide Research Advisory Board for Teva
- advisory board GlaxoSmithKline
- advisory board Regeneron
- advisory board Merck
- advisory board Sanofi
- advisory board Novartis
- advisory board Aviragen
Severe asthma in children is associated with significant morbidity and is a highly heterogeneous disorder with multiple clinical phenotypes. Cluster analyses have been performed in several groups to explain some of the heterogeneity of pediatric severe asthma, which is reviewed in this article. The evaluation of a child with severe asthma includes a detailed diagnostic assessment and excluding other possible diagnoses and addressing poor control due to comorbidities, lack of adherence to asthma controller medications, poor technique, and other psychological and environmental factors. Children with severe asthma require significant resources including regular follow-up appointments with asthma education, written asthma action plan, and care by a multidisciplinary team. Management of pediatric severe asthma now includes emerging phenotypic-directed therapies; however, continued research is still needed to further study the long-term outcomes of pediatric severe asthma and its treatment. (C) 2017 American Academy of Allergy, Asthma & Immunology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据